UTHR
USDUnited Therapeutics Corporation Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$432.750
Kõrge
$440.000
Madal
$430.020
Maht
0.35M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
18.8B
Tööstusharu
Drug Manufacturers - Specialty & Generic
Riik
United States
Kauplemisstatistika
Keskmine maht
0.79M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
United Therapeutics Corporation to Present at Upcoming Investor Conferences
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525
HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics with a Buy and raises the price target from $500 to $525.
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587
RBC Capital analyst Lisa Walter maintains United Therapeutics with a Outperform and raises the price target from $569 to $587.
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423
Wells Fargo analyst Benjamin Burnett maintains United Therapeutics with a Equal-Weight and raises the price target from $414 to $423.
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly
Seotud aktsiad
NTRSO
Northern Trust Corporation Depositary Shares Each Representing a 1/1000th Interest in a Share of Series E Non-Cumulative Perpetual Preferred Stock
FDS
FactSet Research Systems Inc.
PRSO
Peraso Inc.
AQU
Aquaron Acquisition Corp.
ONMDW
OneMedNet Corp Warrant
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.